# Correction: High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs)

## TL;DR

This paper corrects a previous study that found colchicine, an FDA-approved drug, may be effective against a rare type of childhood brain tumor.

## Contribution

The correction addresses errors in the original study's findings and data presentation.

## Key findings

- The original study's data on colchicine's effectiveness against AT/RTs was corrected.
- The revised analysis confirms the need for further validation of the drug's therapeutic potential.

## Abstract

Correction for ‘High-throughput screening of FDA-approved drugs identifies colchicine as a potential therapeutic agent for atypical teratoid/rhabdoid tumors (AT/RTs)’ by Phongthon Kanjanasirirat et al., RSC Adv., 2025, 15, 12331–12341, https://doi.org/10.1039/D5RA01341K.